Movano receives noncompliance notification from Nasdaq
Movano (MOVE) announced that it received a notice from the Listing Qualifications Department of Nasdaq indicating that because the company had not yet filed its Form 10-Q for the quarterly period ended March 31, the company was not in compliance with Nasdaq Listing Rule 5250 requiring Nasdaq-listed companies to timely file all periodic financial reports with the SEC. The Form 10-Q was due on May 15.
Confident Investing Starts Here:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
28 minutes ago
- Business Wire
Law Offices of Frank R. Cruz Encourages Fortrea Holdings Inc. (FTRE) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Fortrea Holdings Inc. ('Fortrea' or the 'Company') (NASDAQ: FTRE) securities between , inclusive (the 'Class Period'). Fortrea investors have until August 1, 2025 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Fortrea Holdings Inc. (FTRE) Investors To Inquire About Securities Fraud Class Action Share IF YOU SUFFERED A LOSS ON YOUR FORTREA HOLDINGS INC. (FTRE) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@ by telephone at (310) 914-5007, or visit our website at What Happened? On September 25, 2024, the investment bank Jefferies downgraded Fortrea from buy to hold, citing perceived weaknesses in the Company's business model as a contract research organization ('CRO') amid pressure on biotechnology funding and that the cost savings Fortrea expects to achieve by existing transition services agreements ('TSAs') are 'not as material as one might think.' On this news, Fortrea's stock price fell $2.73, or 12.3%, to close at $19.48 per share on September 25, 2024, thereby injuring investors. Then, on December 6, 2024, Baird Equity Research stated that '[g]iven our ongoing concerns around the sector, [Fortrea's] choppy history post spin, and lack of clarity on the abrupt communications course change, we cannot recommend an actionable investment (buy or sell)[.]' On this news, Fortrea's stock price fell $1.90, or 8.1%, to close at $21.67 per share on December 6, 2024. Then, on March 3, 2025, before the market opened, Fortrea announced financial results for the fourth quarter and full year 2024, revealing the Company had missed its previously announced guidance for revenue and adjusted EBITDA for the full year 2024. The Company's financial results revealed full year adjusted EBITDA of $202.5 million, well below the Company's previously announced guidance of $220 million to $240 million. The Company also revealed full year revenue of $2.696 billion, which missed previously announced guidance of $2.7 billion to $2.725 billion. The Company further revealed financial guidance for the full year 2025, which projected declines in revenue and adjusted EBITDA, with revenues of $2.450 billion to $2.550 billion and adjusted EBITDA in the range of $170 million to $200 million. Thomas Pike ('Pike'), the Company's then-Chief Executive Officer ('CEO'), explained that 'full-service work for projects from the pre-spin period,' 'have less revenue and less profitability' and 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' Pike further revealed 'this older versus newer mix issue will continue to negatively impact our financial performance during 2025.' On this news, Fortrea shares fell $3.47, or 25.1%, to close at $10.38 per share on March 3, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings; (2) Fortrea overstated the cost savings it would likely achieve by exiting the TSAs; (3) as a result, the Company's previously announced EBITDA targets for 2025 were inflated; (4) accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased Fortrea securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Journals
34 minutes ago
- Business Journals
Highmark Blue Cross Blue Shield expands virtual care to include pelvic health, joint pain
Highmark is continuing its efforts to increase access to health care by offering new ways for members to receive care virtually. The most recent addition is Virtual Pelvic Health, Bloom by Sword, a program designed to address pelvic health dysfunction, such as bladder issues, chronic pelvic pain and other symptoms. Highmark introduced it in July 2024 and has since seen more than 10,000 members enroll. 'Virtual care is an important part of Highmark's overall Living Health strategy,' said Mari Vandenburgh, vice president of health programs and solutions. 'Highmark believes it's our responsibility to make it easier for members to access the care they need when they need it,' Vandenburgh said. 'As an integrated health system, we are in a unique position to break down barriers to care by offering ease of access and use through our virtual solutions that can complement the care members are receiving in person with their provider of choice.' A new approach The Virtual Pelvic Health program is Highmark's second with Sword Health Inc., a New York-based AI health company that specializes in digital health solutions. It is part of Highmark's benefits and available to eligible health plan members at no additional out-of- pocket cost. Participants simply enroll in the program through the My Highmark app or member portal. Once enrolled, participants are matched with a pelvic health clinician and receive an FDA-listed insertable device and access to a mobile app. A personalized set of pelvic floor exercises are recommended, and the sensor and app work together to monitor the force, endurance and accuracy of the pelvic floor muscles during the exercises. 'That real-time feedback helps participants maximize their results,' Vandenburgh said. 'The Virtual Pelvic Health program provides convenient, on-demand access to pelvic floor care that is focused on both strengthening and relaxation,' she said. 'The combination of the sensor and the feedback that a user receives in the app really helps to monitor progress in their program. The app also provides educational resources to individuals that help to support behavior change and habit formation in the population of individuals that could benefit from pelvic floor support.' Participants have reported significant improvements in their quality of life, including a reduction in symptoms they previously experienced. Additionally, the program has helped alleviate the stigma often associated with pelvic floor conditions, improving mental health. Virtual joint health The Virtual Pelvic Health program follows Highmark's introduction of Virtual Joint Health, Thrive by Sword to self-funded plans in 2022. In that program, a licensed physical therapist assigns a series of exercises for people looking to alleviate musculoskeletal pain based on their specific goals. Participants then receive a tablet they can use at home as they complete the exercises. The tablet is equipped with advanced motion sensing technology to provide real-time feedback and ensure people use proper form. It also shares data with their physical care specialist to monitor progress and, if necessary, adjust their recommended exercise plan to better accommodate their needs. 'It really enables members to address their joint health needs at the time that's most convenient for them,' Vandenburgh said. 'They can do the exercises in the comfort of their own home, and it reduces the barriers of time and access to care if there are delays in getting appointments.' In 2024, the insurer expanded it to fully insured plans. So far, more than 36,000 Highmark members have enrolled in the program. The feedback has been positive, Vandenburgh said, with 88% of participants describing it as easy to use and 72% completing the program. Health outcomes also have been strong, with 69% of participants reporting a significant improvement in their joint pain and 35% reduction in the intent to pursue surgery to address their pain. 'Another positive outcome that users report is that 26% say they saw an improvement in their work and productivity impairment,' she said. 'We're also monitoring the behavioral health impacts of joint health and increasing screenings for depression and anxiety.' Expanded reach Highmark's virtual care offerings include a virtual triage tool, virtual primary care, a virtual urgent care clinic and virtual specialty care clinics for behavioral health, women's health and dermatology, as well as a digital diabetes management solution. Offering on-demand, virtual care helps people get the care they need to improve their health while lowering costs, Vandenburgh said. The Virtual Joint Health program, for example, has reduced costs by $112 per member per month in comparison to a control group. That savings can then be reinvested back into delivering a remarkable health experience, so it's easier for members to engage and manage their health. 'Virtual Joint Health and Virtual Pelvic Health deliver a win-win combination by boosting employer productivity and lowering cost, while simultaneously enabling employees convenient access to care and improved quality of life,' she said. 'We see continued growth in engagement and enrollment in our digital solutions and programs year over year.' To learn more visit Lauren Lawley Head is a freelance writer.
Yahoo
39 minutes ago
- Yahoo
'Web-Surfing With Your Brain' by 2030? Neuralink's $9B Valuation Sparks Debate Over Musk's Telepathy Timeline
Elon Musk's brain-computer interface company Neuralink has raised $600 million in new funding at a $9 billion valuation, according to Semafor. The fundraising round follows the company's first human implant earlier this year and expands its efforts to develop medical applications for its brain chip technology. Musk has previously stated that humans may be able to surf the web with their thoughts by the end of 2030, Reuters reported. The claim has drawn renewed attention amid the funding news. In January, MIT Technology Review noted that neuroscience experts have questioned the feasibility of this timeline. Don't Miss:Invest where it hurts — and help millions heal:. Neuralink began human trials in 2024 after receiving U.S. Food and Drug Administration approval to implant its brain-computer interface, or BCI, in paralysis patients. The first participant, Noland Arbaugh, underwent surgery in January 2024 and was later shown controlling a computer cursor and playing online chess using only his thoughts, according to Reuters. In May 2024, Neuralink registered a clinical study in the U.S. government trials database, aiming to enroll three participants. The company is also expanding its trial footprint internationally, having received approval from Health Canada in November 2024 to recruit six patients for a study testing the device's safety and efficacy in enabling cursor movement through brain activity. Trending: Maximize saving for your retirement and cut down on taxes: . While early demonstrations suggest meaningful progress, the technology remains highly experimental. Neuralink is currently conducting an early feasibility study called the Precise Robotically Implanted Brain-Computer Interface, with three participants implanted. The company has not yet registered a pivotal trial — the FDA-required phase for commercial approval — and continues to modify its device design, including electrode and surgical robot upgrades, according to MIT Technology Review. Neuralink's valuation has risen sharply to $9 billion, up from an estimated $5 billion in mid-2023, according to Semafor. The publication reported that the recent funding round drew support from existing investors aligned with Elon Musk's other companies, including Tesla Inc. (NASDAQ:TSLA) and SpaceX. Musk has repeatedly positioned Neuralink as a safeguard against artificial intelligence threats. In a May 2 post on X, he stated that Neuralink's brain chips must become widely available to ensure humans remain competitive as AI advances. He previously told CNN in 2023 that brain-computer interfaces could help reduce civilizational risk posed by artificial general global BCI market is projected to reach $6.52 billion by 2030, growing at a compound annual growth rate of 18.15% from 2025 to 2030, according to Grand View Research. Competitors are also gaining traction. Synchron was the first to receive FDA approval to implant a BCI in U.S. patients, and Precision Neuroscience recently announced regulatory clearance for its minimally invasive device. As Neuralink expands its human trials, it faces pressure to keep pace with rivals and regulatory scrutiny. According to Reuters, FDA found quality control issues in the company's animal research lab, and U.S. Department of Agriculture's Inspector General have raised concerns over the pace and integrity of its experiments. With significant competition, regulatory hurdles, and ethical concerns in play, Neuralink's ability to deliver on Musk's ambitious timeline will remain under close watch by investors, scientists, and the public alike. Read Next: Can you guess how many retire with a $5,000,000 nest egg? . Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? TESLA (TSLA): Free Stock Analysis Report This article 'Web-Surfing With Your Brain' by 2030? Neuralink's $9B Valuation Sparks Debate Over Musk's Telepathy Timeline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
